Latest Breaking News On - யாகோவ் நாஹ்மியச் - Page 9 : comparemela.com

Veteran drug could prevent Covid lung damage, study shows

Veteran drug could prevent Covid lung damage, study shows Fenofibrate (Tricor) could potentially turn Covid from a devastating disease into a far more manageable form of a respiratory cold. December 23, 2020, 10:59 am Healthcare workers at work at the coronavirus ward of Shaare Zedek Medical Center in Jerusalem. Photo by Olivier Fitoussi/Flash90 Initial data from a new study shows that a well-established drug could prevent lung damage in Covid-19 patients, potentially reducing its severity and mortality rates and turning it from a devastating disease into a far more manageable form of a respiratory cold. Back in July, a study led by the Hebrew University of Jerusalem demonstrated that Covid-19 inhibits the effective breakdown in lungs and that the resulting buildup of fats in lung cells play a critical role in the deterioration of patients’ condition.

Israel generalUnited statesShlomo maayanYaakov nahmiasDaniel hanoch nahmiasDaniel hanochHebrew university of jerusalemDepartment of infectious diseasesHebrew universityBarzilai medicalSouth americaInfectious diseasesஇஸ்ரேல் ஜநரல்ஒன்றுபட்டது மாநிலங்களில்ஶ்லமொ மாயன்யாகோவ் நாஹ்மியச்

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19 In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem s Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19. The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.

Israel generalUnited statesHebrew universityTel avivOren shibolethShlomo maayanYaakov nahmiasFenofibrate tricorEmily hendersonIchilov medical centerSigal shafram tikva at hadassah medical centerJerusalem hebrew universityDepartment of infectious diseasesGeneric drug repurposingProfessor yaakov nahmiasBarzilai hospital

Promising clinical data for fenofibrate s ability to prevent lung damage in COVID patients

Credit: Daniel Hanoch In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem s Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19. The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.

Israel generalUnited statesHebrew universityTel avivOren shibolethShlomo maayanYaakov nahmiasFenofibrate tricorIchilov medical centerSigal shafram tikva at hadassah medical centerJerusalem hebrew universityDepartment of infectious diseasesGeneric drug repurposingProfessor yaakov nahmiasBarzilai hospitalSouth america

Promising clinical data for fenofibrate s ability to prevent lung damage in COVID-19 patients

Promising clinical data for fenofibrate s ability to prevent lung damage in COVID-19 patients
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Israel generalUnited statesHebrew universityTel avivOren shibolethShlomo maayanDavid hanochYaakov nahmiasFenofibrate tricorIchilov medical centerSigal shafram tikva at hadassah medical centerJerusalem hebrew universityDepartment of infectious diseasesNahmias lab at hebrew universityGeneric drug repurposingProfessor yaakov nahmias

Initial Hebrew U Clinical Data Support Fenofibrate s Effectiveness in Preventing Lung Damage in Corona Patients | The Jewish Press - JewishPress com | David Israel | 6 Tevet 5781 – December 21, 2020

Initial Hebrew U Clinical Data Support Fenofibrate s Effectiveness in Preventing Lung Damage in Corona Patients | The Jewish Press - JewishPress com | David Israel | 6 Tevet 5781 – December 21, 2020
jewishpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jewishpress.com Daily Mail and Mail on Sunday newspapers.

United statesIsrael generalHebrew universityTel avivOren shibolethShlomo maayanYaakov nahmiasDennis sylvester hurdDaniel hanochIchilov medical centerSigal shafram tikva at hadassah medical centerAbbott laboratoriesDepartment of infectious diseasesPhoto creditProfessor yaakov nahmiasBarzilai hospital